Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia

We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with Confirmed undet...

Descripción completa

Detalles Bibliográficos
Autores: Moreno, Carol|||0000-0003-3275-0271, Solman, Isabelle G., Tam, Constantine S.|||0000-0002-9759-5017, Grigg, Andrew, Scarfò, Lydia|||0000-0002-0844-0989, Kipps, Thomas J.|||0000-0002-0064-4549, Srinivasan, Srimathi, Mali, Raghuveer Singh, Zhou, Cathy, Dean, James P., Szafer-Glusman, Edith, Choi, Michael
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:289224
Acceso en línea:https://ddd.uab.cat/record/289224
https://dx.doi.org/urn:doi:10.1182/bloodadvances.2023010236
Access Level:acceso abierto
Palabra clave:Lymphoid neoplasia
id ES_b4ef70425cbc016e2eb5f62e2b6cacec
oai_identifier_str oai:ddd.uab.cat:289224
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemiathe phase 2 CAPTIVATE studyMoreno, Carol|||0000-0003-3275-0271Solman, Isabelle G.Tam, Constantine S.|||0000-0002-9759-5017Grigg, AndrewScarfò, Lydia|||0000-0002-0844-0989Kipps, Thomas J.|||0000-0002-0064-4549Srinivasan, SrimathiMali, Raghuveer SinghZhou, CathyDean, James P.Szafer-Glusman, EdithChoi, MichaelLymphoid neoplasiaWe evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with Confirmed undetectable MRD (uMRD) were randomly assigned to placebo or ibrutinib groups; patients without Confirmed uMRD were randomly assigned to ibrutinib or ibrutinib plus venetoclax groups. We compared immune cell subsets in samples collected at 7 time points with age-matched healthy donors. CLL cells decreased within 3 cycles after venetoclax initiation; from cycle 16 onward, levels were similar to healthy donor levels (HDL; ≤0.8 cells per μL) in patients with Confirmed uMRD and slightly above HDL in patients without Confirmed uMRD. By 4 months after cycle 16, normal B cells had recovered to HDL in patients randomly assigned to placebo. Regardless of randomized treatment, abnormal counts of T cells, classical monocytes, and conventional dendritic cells recovered to HDL within 6 months (median change from baseline -49%, +101%, and +91%, respectively); plasmacytoid dendritic cells recovered by cycle 20 (+598%). Infections generally decreased over time regardless of randomized treatment and were numerically lowest in patients randomly assigned to placebo within 12 months after cycle 16. Sustained elimination of CLL cells and recovery of normal B cells were confirmed in samples from patients treated with fixed-duration ibrutinib plus venetoclax in the GLOW study (NCT03462719). These results demonstrate promising evidence of restoration of normal blood immune composition with ibrutinib plus venetoclax. 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/289224https://dx.doi.org/urn:doi:10.1182/bloodadvances.2023010236reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2892242026-06-06T12:50:31Z
dc.title.none.fl_str_mv Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
the phase 2 CAPTIVATE study
title Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
spellingShingle Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
Moreno, Carol|||0000-0003-3275-0271
Lymphoid neoplasia
title_short Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
title_full Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
title_fullStr Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
title_full_unstemmed Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
title_sort Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia
dc.creator.none.fl_str_mv Moreno, Carol|||0000-0003-3275-0271
Solman, Isabelle G.
Tam, Constantine S.|||0000-0002-9759-5017
Grigg, Andrew
Scarfò, Lydia|||0000-0002-0844-0989
Kipps, Thomas J.|||0000-0002-0064-4549
Srinivasan, Srimathi
Mali, Raghuveer Singh
Zhou, Cathy
Dean, James P.
Szafer-Glusman, Edith
Choi, Michael
author Moreno, Carol|||0000-0003-3275-0271
author_facet Moreno, Carol|||0000-0003-3275-0271
Solman, Isabelle G.
Tam, Constantine S.|||0000-0002-9759-5017
Grigg, Andrew
Scarfò, Lydia|||0000-0002-0844-0989
Kipps, Thomas J.|||0000-0002-0064-4549
Srinivasan, Srimathi
Mali, Raghuveer Singh
Zhou, Cathy
Dean, James P.
Szafer-Glusman, Edith
Choi, Michael
author_role author
author2 Solman, Isabelle G.
Tam, Constantine S.|||0000-0002-9759-5017
Grigg, Andrew
Scarfò, Lydia|||0000-0002-0844-0989
Kipps, Thomas J.|||0000-0002-0064-4549
Srinivasan, Srimathi
Mali, Raghuveer Singh
Zhou, Cathy
Dean, James P.
Szafer-Glusman, Edith
Choi, Michael
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Lymphoid neoplasia
topic Lymphoid neoplasia
description We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with Confirmed undetectable MRD (uMRD) were randomly assigned to placebo or ibrutinib groups; patients without Confirmed uMRD were randomly assigned to ibrutinib or ibrutinib plus venetoclax groups. We compared immune cell subsets in samples collected at 7 time points with age-matched healthy donors. CLL cells decreased within 3 cycles after venetoclax initiation; from cycle 16 onward, levels were similar to healthy donor levels (HDL; ≤0.8 cells per μL) in patients with Confirmed uMRD and slightly above HDL in patients without Confirmed uMRD. By 4 months after cycle 16, normal B cells had recovered to HDL in patients randomly assigned to placebo. Regardless of randomized treatment, abnormal counts of T cells, classical monocytes, and conventional dendritic cells recovered to HDL within 6 months (median change from baseline -49%, +101%, and +91%, respectively); plasmacytoid dendritic cells recovered by cycle 20 (+598%). Infections generally decreased over time regardless of randomized treatment and were numerically lowest in patients randomly assigned to placebo within 12 months after cycle 16. Sustained elimination of CLL cells and recovery of normal B cells were confirmed in samples from patients treated with fixed-duration ibrutinib plus venetoclax in the GLOW study (NCT03462719). These results demonstrate promising evidence of restoration of normal blood immune composition with ibrutinib plus venetoclax.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/289224
https://dx.doi.org/urn:doi:10.1182/bloodadvances.2023010236
url https://ddd.uab.cat/record/289224
https://dx.doi.org/urn:doi:10.1182/bloodadvances.2023010236
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417301432860672
score 15,300719

Similares en LA Referencia